Ken Griffin’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.19M | Buy |
446,606
+122,157
| +38% | +$1.7M | ﹤0.01% | 3996 |
|
|
2025
Q4 | $4.56M | Buy |
324,449
+190,167
| +142% | +$2.67M | ﹤0.01% | 4430 |
|
|
2025
Q3 | $1.88M | Buy |
134,282
+34,080
| +34% | +$490K | ﹤0.01% | 6195 |
|
|
2025
Q2 | $1.51M | Sell |
100,202
-59,361
| -37% | -$848K | ﹤0.01% | 6246 |
|
|
2025
Q1 | $2.1M | Buy |
+159,563
| New | +$2.2M | ﹤0.01% | 5446 |
|
|
2024
Q3 | – | Sell |
-38,405
| Closed | -$618K | – | 15063 |
|
|
2024
Q2 | $585K | Buy |
38,405
+3,225
| +9% | +$46.2K | ﹤0.01% | 7733 |
|
|
2024
Q1 | $516K | Sell |
35,180
-517,365
| -94% | -$7.55M | ﹤0.01% | 8320 |
|
|
2023
Q4 | $7.69M | Sell |
552,545
-306,695
| -36% | -$4.1M | ﹤0.01% | 3186 |
|
|
2023
Q3 | $11.5M | Sell |
859,240
-623,850
| -42% | -$8.44M | ﹤0.01% | 2508 |
|
|
2023
Q2 | $18.7M | Buy |
1,483,090
+544,345
| +58% | +$6.35M | ﹤0.01% | 1958 |
|
|
2023
Q1 | $10.7M | Buy |
938,745
+499,430
| +114% | +$5.39M | ﹤0.01% | 2726 |
|
|
2022
Q4 | $4.55M | Buy |
+439,315
| New | +$4.74M | ﹤0.01% | 4008 |
|
|
2022
Q3 | – | Sell |
-282,700
| Closed | -$3.13M | – | 13439 |
|
|
2022
Q2 | $3.13M | Buy |
282,700
+196,310
| +227% | +$2.13M | ﹤0.01% | 4683 |
|
|
2022
Q1 | $963K | Buy |
+86,390
| New | +$979K | ﹤0.01% | 7790 |
|
|
2021
Q4 | – | Sell |
-83,115
| Closed | -$1.05M | – | 14578 |
|
|
2021
Q3 | $1.08M | Sell |
83,115
-57,190
| -41% | -$762K | ﹤0.01% | 7944 |
|
|
2021
Q2 | $2.06M | Sell |
140,305
-32,315
| -19% | -$452K | ﹤0.01% | 6545 |
|
|
2021
Q1 | $2.12M | Buy |
172,620
+156,370
| +962% | +$2.01M | ﹤0.01% | 6254 |
|
|
2020
Q4 | $232K | Sell |
16,250
-63,210
| -80% | -$851K | ﹤0.01% | 9514 |
|
|
2020
Q3 | $1.1M | Buy |
79,460
+30,785
| +63% | +$367K | ﹤0.01% | 5863 |
|
|
2020
Q2 | $516K | Buy |
48,675
+15,360
| +46% | +$156K | ﹤0.01% | 7015 |
|
|
2020
Q1 | $269K | Buy |
+33,315
| New | +$278K | ﹤0.01% | 7519 |
|
|
2019
Q4 | – | Sell |
-80,575
| Closed | -$611K | – | 9640 |
|
|
2019
Q3 | $611K | Sell |
80,575
-138,075
| -63% | -$1.03M | ﹤0.01% | 6416 |
|
|
2019
Q2 | $1.64M | Buy |
218,650
+94,260
| +76% | +$741K | ﹤0.01% | 4859 |
|
|
2019
Q1 | $1.01M | Buy |
124,390
+82,620
| +198% | +$628K | ﹤0.01% | 5573 |
|
|
2018
Q4 | $315K | Buy |
+41,770
| New | +$294K | ﹤0.01% | 7179 |
|
|
2018
Q3 | – | Sell |
-320,240
| Closed | -$2.06M | – | 9605 |
|
|
2018
Q2 | $2.06M | Buy |
+320,240
| New | +$2.02M | ﹤0.01% | 4064 |
|
|
2017
Q4 | – | Sell |
-40,015
| Closed | -$288K | – | 8354 |
|
|
2017
Q3 | $286K | Buy |
+40,015
| New | +$288K | ﹤0.01% | 6153 |
|
|
2014
Q3 | – | Sell |
-58,150
| Closed | -$502K | – | 8350 |
|
|
2014
Q2 | $502K | Buy |
58,150
+6,475
| +13% | +$54.5K | ﹤0.01% | 4386 |
|
|
2014
Q1 | $453K | Sell |
51,675
-28,150
| -35% | -$245K | ﹤0.01% | 4481 |
|
|
2013
Q4 | $655K | Buy |
+79,825
| New | +$632K | ﹤0.01% | 3698 |
|
Other funds holding RDY
AIM
Ken Griffin's RDY Position: Q1 2026 in Review
Ken Griffin increased its Dr. Reddy's Laboratories (RDY) stake by 38% in Q1 2026, buying an estimated $1.7M and bringing the position to 446,606 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3996.
Ken Griffin first reported a position in RDY in Q4 2013 and has held it in 30 quarters since. The position peaked at $18.7M in Q2 2023. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.
- Ken Griffin held 446,606 shares of Dr. Reddy's Laboratories worth $6.19M as of Q1 2026.
- Ken Griffin bought 122,157 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $1.7M.
- Dr. Reddy's Laboratories made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3996 holding.
- Ken Griffin first reported a position in Dr. Reddy's Laboratories in Q4 2013 and has held it in 30 quarters since.
- Ken Griffin's Dr. Reddy's Laboratories position peaked at $18.7M in Q2 2023.
- 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.